Swidzińska E, Ossolińska M, Naumnik W, Trojan S, Chyczewska E
Department of Lung Diseases and Tuberculosis, Medical University of Białystok, Poland.
Rocz Akad Med Bialymst. 2005;50:197-200.
The purpose of our study was to evaluate the clinical usefulness of serum endostatin levels during chemotherapy of lung cancer in relation to the histopathological type of the tumor, clinical stage and response to therapy.
Serum concentrations of endostatin were determined in 37 patients (24 with non-small cell lung cancer and 13 with small cell lung cancer), 10 healthy subjects constituted controls. To determine endostatin levels (ELISA), venous blood samples were collected from each patient before treatment and after 4-6 courses of chemotherapy.
The serum concentrations of endostatin were found significantly higher in patients in comparison with controls (p=0.003). No statistically significant differences were established between the concentrations of endostatin with regard to such clinical features, as: performance status, clinical stage (III and IV) and histopathological type (non-small cell lung cancer and small cell lung cancer). The concentrations of endostatin did not change after chemotherapy. There was no change of endostatin concentration caused by the response to treatment.
The serum endostatin concentrations were elevated in lung cancer patients.
我们研究的目的是评估肺癌化疗期间血清内皮抑素水平与肿瘤组织病理学类型、临床分期及治疗反应之间的临床相关性。
测定了37例患者（24例非小细胞肺癌患者和13例小细胞肺癌患者）的血清内皮抑素浓度，10名健康受试者作为对照。为了测定内皮抑素水平（酶联免疫吸附测定法），在治疗前及4 - 6个化疗疗程后从每位患者采集静脉血样本。
发现患者血清内皮抑素浓度显著高于对照组（p = 0.003）。在内皮抑素浓度方面，未发现与以下临床特征存在统计学显著差异：体能状态、临床分期（III期和IV期）以及组织病理学类型（非小细胞肺癌和小细胞肺癌）。化疗后内皮抑素浓度未发生变化。治疗反应未导致内皮抑素浓度改变。
肺癌患者血清内皮抑素浓度升高。
